International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares

BI SPEVIGO graphic

Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”Boehringer Ingelheim’s spesolimab was granted conditional marketing authorization from the European Commission (EC) to treat generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP. This conditional approval is based on Phase II clinical trial results for EFFISAYIL® 1. Carinne Brouillon, Member of the Board of Managing Directors responsible for Human Pharma, Boehringer Ingelheim stated, “We are delighted to be able to bring this much needed treatment to patients with GPP, whose options were incredibly limited until this year. This approval marks another significant milestone in the continued development of spesolimab in neutrophilic skin diseases, which we are investigating in further clinical trials.”

Boehringer Ingelheim A Value Through Innovation

Categories

Recent Posts

Shining a Spotlight on our 2022 Fellows: Get to Know the Future Leaders in Psoriasis – Albert Duvetorp, MD, PhD

Medical Adherence in Topical Agents in the Context of Psoriasis Patients

Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics

Also Read

Press Release

Sotyktu™ (Deucravacitinib) Recommended by the National Institute for Health and Care Excellence (NICE) for use in England as a First-in-class Treatment Option for Moderate to Severe Plaque Psoriasis in Adults

Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.